Eli Lilly and Co (BUE:LLY) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:LLY Eli Lilly and Co BUE:LLY
97 GF Score
Price ARS32,160.00
GF Value ARS39,044.32
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BUE:LLY
97GF Score
Eli Lilly and Co BUE:LLY
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (BUE:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of ARS32,160.00 is trading 17.6% below its estimated GF Value™ of ARS39,044.32. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for BUE:LLY:

  • Dividends Received:
  • GF Value™: ARS39,044.32 vs. price of ARS32,160.00 (17.6% below fair value)
  • GF Score™: 97/100 with 4 warning signs

No single metric tells the full story. See the BUE:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for BUE:LLY

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS32,160.00
Price
ARS39,044.32
GF Value